Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients

Cancer

Volumn 115, Issue 2, 2009, Pages 355-362

  Maertens, Johan ^a   Buvé, Kristel ^a   Theunissen, Koen ^b   Meersseman, Wouter ^a   Verbeken, Eric ^a   Verhoef, Gregor ^a   Van Eldere, Johan ^a   Lagrou, Katrien ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VIRGA JESSE HOSPITAL   (Belgium)

Author keywords

Aspergillosis; Galactomannan; Neutropenic; Outcome; Surrogate marker; Survival

Indexed keywords

GALACTOMANNAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; AUTOPSY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HEMATOLOGIC DISEASE; HOSPITAL DISCHARGE; HUMAN; KAPPA STATISTICS; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MONITORING; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPERGILLOSIS; AUTOPSY; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MANNANS; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 59549103760     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24022     Document Type: Article

References (25)

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266.
2. Hope W, Walsh T, Denning D. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5:609-622.
3. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis. 2006;43:1449-1455.
4. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253-259.
5. Miceli MH, Maertens J, Buve K, et al. Immune reconstitu-tion inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer. 2007;110:112-120.
6. Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organization for Research and Treatment of Cancer and the Global Asper-gillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
7. Cornely OA, Maertens J, Bresnik M, et al. AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBi-Load trial). Clin Infect Dis. 2007;44:1289-1297.
8. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer. 2008;112:2309-2312.
9. Mennink-Kersten M, Donnelly J, Verweij P. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4:349-357.
10. Wheat L. Galactomannan antigen detection for diagnosis of invasive aspergillosis, part I. Clin Microbiol Newsl. 2005;27:52-58.
11. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol. 1999;37:3223-3228.
12. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604-1610.
13. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in 2 adult and pedi-atric haematology units during a 4-year prospective study. Cancer. 2001;91:311-318.
14. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive asper-gillosis in cancer patients. J Clin Oncol. 2002;20:1898-1906.
15. Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
16. Anaissie E. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis. 2007;44:1298-1306.
17. Woods G, Miceli M, Grazziutti M, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis. A study of 56 patients with hematologic cancer. Cancer. 2007; 110:830-834.
18. Ascioglu S, Rex JH, De Pauw B, et al. on behalf of the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
19. Maertens J, Theunissen K, Verhoef G, et al. Galacto-mannan and computed tomography-based preemptive anti-fungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242-1250.
20. Segal B, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-683.
21. Kraemer HC, Periyakoil VS, Noda A. Kappa coefficients medical research. Stat Med. 2002;21:2109-2129.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
23. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with hematological disorders. Mycoses. 2007;50(suppl 1):2-17.
24. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis. 2008; 46:1412-1422.
25. Marr KA. Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy? Clin Infect Dis. 2008;46:1423-1425.